Security

Visa to Acquire Fraud Intelligence Firm BioCatch for $2.4 Billion

The payments giant says BioCatch's behavioral and device intelligence will help financial institutions combat account takeovers, scams and other forms of digital fraud.

A
By Aisha Rahman Health Reporter
August 3, 2026 / 5 min read

Visa has agreed to acquire BioCatch, the behavioral biometrics and fraud intelligence firm, for $2.4 billion, SecurityWeek reported on August 3. The acquisition is one of the largest dedicated fraud-prevention deals of the year and a marker of how seriously the payments industry is taking AI-driven scams.

What BioCatch Does

BioCatch analyzes more than 2,000 behavioral and device signals - mouse movements, keystroke rhythms, touch pressure, screen orientation, session patterns - to distinguish legitimate users from fraudsters. The technology is deployed across more than 130 financial institutions globally, including several of the world's largest retail banks. BioCatch's customers have used the platform to block hundreds of millions of dollars in fraud attempts.

"The payments giant says BioCatch's behavioral and device intelligence will help financial institutions combat account takeovers, scams and other forms of digital fraud," SecurityWeek reported.

Why Visa Wants It

Visa has long provided fraud-prevention services through its Visa Advanced Authorization and Visa Risk Manager platforms. BioCatch adds a behavioral layer that complements Visa's network-level analytics. The combination is designed to give issuing banks and merchants a single integrated stack for detecting account takeover, authorized push payment fraud, and synthetic identity fraud - categories that have grown rapidly with AI-driven phishing and voice cloning.

The Deal Math

The $2.4 billion price implies a roughly 15x revenue multiple for BioCatch. The company was last valued at around $1 billion in its 2022 funding round. BioCatch's revenue has reportedly grown more than 40% year over year since then. The acquisition is expected to close in Q4 2026, subject to regulatory approval in the EU and US.

Tagged

Comments (0)

No comments yet. Be the first to share your thoughts.